Emyria Ltd (ASX:EMD) has expanded its clinical service subsidiary - Emerald Clinics - with the addition of a second consulting suite in Perth, which provides the potential to double the capacity of Perth and builds on the recent expansion in Melbourne.
This expansion comes off the back of record patient appointments in January 2021 and a recently announced expansion in Victoria.
The additional clinical rooms will also help support the pivotal clinical trials, currently in planning, in support of the registration of EMD-003, a cannabinoid medicine targeting unmet needs in mental health.
Demand up every month
Emyria managing director Dr Michael Winlo said: “Western Australia was the first Emerald Clinics location.
“Demand for our services from both patients and referring doctors has grown every month since we opened.
“We anticipate this expansion will allow us to improve our waiting times and see more patients which, in turn, improves our proprietary data asset (Emyria Data).
“Insights from Emyria Data is now informing the design and planning of pivotal drug registration clinical trials for our first drug program, EMD-003 - a cannabinoid medicine targeting unmet needs in mental health.
“The additional clinical capacity in Perth also allows us to support a wider range of clinical trials in different indications as well as help us deliver on the recently awarded Future Health Research and Innovation Grant involving our TGA-registered remote monitoring system.”
New consulting rooms
The new Perth suite has the capacity for four additional consulting rooms and is co-located within the site of West Leederville Private Hospital complex.
The Perth expansion will boost clinical capacity in WA and support Emyria to:
- Improve patient access to Emerald Clinics services;
- Conduct pivotal clinical trials currently being planned for Emyria’s first drug development program, EMD-003 and seeking registration as a Schedule 3 medicine; and
- Deliver on a recently awarded grant from the WA Government. The grant award of $880,000 was won with research partner, the University of Western Australia. Emyria’s technology and team will play a lead role monitoring the clinical and mental health of vulnerable patients remotely.
The second Perth Emerald Clinics location is at 2 McCourt Street, West Leederville.
Additional clinical rooms will also help support the pivotal clinical trials, currently in planning, in support of the registration of EMD-003, a cannabinoid medicine targeting unmet needs in mental health.